A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Completed
Eli Lilly and Company
Phase 2
2003-04-01
The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as
prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also
referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in
the heart using a catheter (a long thin tube) that has a small balloon on the end. In many
cases, patients who have this procedure receive a stent, a small wire spring that helps keep
the vessel open.
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
Completed
Daiichi Sankyo Inc.
Phase 3
2004-11-01
The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as
a possible treatment for patients with acute coronary syndrome (heart attack or chest pain)
who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a
balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is
better at reducing deaths, future heart attacks, or stroke.
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
Completed
Daiichi Sankyo, Inc.
Phase 3
2004-11-01
The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as
a possible treatment for patients with acute coronary syndrome (heart attack or chest pain)
who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a
balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is
better at reducing deaths, future heart attacks, or stroke.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
